MexBrain
- Industry
- Biotechnology
- Founded Year
- 2017
- Headquarters
- Villeurbanne, France
- Employee Count
- 14
Key People
- Thomas Brichart - Founder & CEO
- Sebastien Groyer - Chief Business Officer
Assessment
- Team
-
Aspect: First-time 10+ yrs
Summary: The leadership team includes experienced professionals with significant industry experience.
The presence of seasoned professionals in key roles suggests a strong foundation for strategic decision-making and operational execution.
- Clinical Need
-
Aspect: Very Strong
Summary: MexBrain addresses critical conditions involving metal toxicity, such as Wilson's Disease and Acute Kidney Injury.
The company's focus on severe health conditions with limited treatment options highlights a significant unmet clinical need, indicating strong market demand.
- Competition
-
Aspect: First mover
Summary: MexBrain appears to be pioneering in the specific niche of metal extraction via dialysis.
Being an early entrant in this specialized field may provide a competitive advantage, though the emergence of competitors could alter this dynamic.
- Technical Challenge
-
Aspect: Complex
Summary: Developing superchelating polymers for dialysis machines involves significant technical complexity.
The intricate nature of the technology may pose challenges in development and scalability, potentially impacting time-to-market and cost.
- Patent
-
Aspect: Strong
Summary: MexBrain holds multiple patents related to metal extraction technologies.
A robust patent portfolio can provide a competitive edge and protect intellectual property, enhancing the company's valuation and attractiveness to investors.
- Financing
-
Aspect: Medium
Summary: The company has secured funding through Series A and non-equity assistance rounds.
While initial funding is secured, additional capital may be required to support ongoing research, clinical trials, and commercialization efforts.
- Regulatory
-
Aspect: Running FIH
Summary: MexBrain is conducting pilot clinical trials in Europe.
Progressing through early-stage clinical trials is a positive indicator of potential regulatory approval, though further stages remain.
Opportunity Rollup
- Odds of Success
- 3.85
- Peak Market Share
- 5.35
- Segment CAGR
- 5.9%
- Market Segment
- Nephrology and Urology Devices
- Market Sub Segment
- Dialysis Equipment
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.27 |
| 2 | 0.80 |
| 3 | 1.87 |
| 4 | 3.74 |
| 5 | 5.35 |
Key Takeaway
MexBrain's innovative approach to treating metal toxicity positions it well in a growing market, though technical and financial challenges remain.